Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
February 12, 2026
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
February 11, 2026
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
January 06, 2026
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
Leadership in Sleep Medicine
Hear from our Chief Operating Officer Blair Jackson as he shares his perspective on Alkermes’ recently-completed acquisition of Avadel Pharmaceuticals plc.
Understanding Narcolepsy
Narcolepsy is a rare neurological disorder that is often misunderstood and stigmatized. Our team members describe the physical symptoms that people living with this sleep disorder face, along with the emotional and psychological impact, in a video created to foster understanding.
Notable Recognition
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes by leading news and ranking organizations.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Sodium oxybate extended-release oral suspension
-
Idiopathic Hypersomnia
Phase 3
Overview
A once-nightly formulation of sodium oxybate for extended-release oral suspension is currently approved for people 7 years of age or older with narcolepsy in the U.S.
Clinical TrialsA once-nightly formulation of sodium oxybate for extended-release oral suspension is currently being evaluated for use in adults with idiopathic hypersomnia in a phase 3 study, REVITALYZ. For more information about this study, please visit clinicaltrials.gov/study/NCT06525077.
-
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
OverviewOlanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Clinical TrialsOlanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study, ENLIGHTEN-Youth. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
Alixorexton
-
Narcolepsy Type 1
Phase 2
-
Narcolepsy Type 2
Phase 2
-
Idiopathic Hypersomnia
Phase 2
OverviewAlixorexton (formerly ALKS 2680) is an investigational, oral orexin 2 receptor agonist in development for the treatment of narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Clinical TrialsVibrance-1 and Vibrance-2, phase 2 studies evaluating alixorexton in adults with narcolepsy type 1 and narcolepsy type 2, respectively, are complete and phase 3 studies are expected to initiate in Q1 2026. Vibrance-3, a phase 2 study in adults with idiopathic hypersomnia is ongoing. Participants who complete one of the Vibrance studies have the option to continue in a long-term, open-label, safety study evaluating the safety of alixorexton for up to two years.
For more information about enrolling studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:- Vibrance-3: clinicaltrials.gov/study/NCT06843590
- Open-label Extension: clinicaltrials.gov/study/NCT06767683
-
